An open-label multiyear study of sargramostim-treated Parkinson ’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

ConclusionsTaken together, the data affirmed long-term safety as well as immune and anti-inflammatory responses reflecting clinical stability in PD under the sargramostim treatment. Confirmation in larger patient populations is planned in a future phase II evaluation.Trial registration: ClinicalTrials.gov: NCT03790670, Date of Registration: 01/02/2019, URL:https://clinicaltrials.gov/ct2/show/NCT03790670?cond=leukine+parkinson%27s&draw=2&rank=2.
Source: Translational Neurodegeneration - Category: Neurology Source Type: research